Cartesian Therapeutics (NASDAQ:RNAC) Receives “Outperform” Rating from Wedbush

Wedbush restated their outperform rating on shares of Cartesian Therapeutics (NASDAQ:RNAC) in a research note issued to investors on Tuesday morning,Benzinga reports. They currently have a $38.00 target price on the stock.

Other analysts have also recently issued reports about the company. Cantor Fitzgerald upgraded Cartesian Therapeutics from a “neutral” rating to an “overweight” rating and set a $16.00 price target on the stock in a report on Monday. Needham & Company LLC reiterated a “buy” rating and issued a $42.00 price objective on shares of Cartesian Therapeutics in a report on Monday. BTIG Research reiterated a “buy” rating on shares of Cartesian Therapeutics in a research report on Monday. HC Wainwright cut their price target on shares of Cartesian Therapeutics from $40.00 to $30.00 and set a “buy” rating on the stock in a research report on Wednesday, November 19th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Cartesian Therapeutics in a report on Monday, December 29th. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Cartesian Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $34.00.

Cartesian Therapeutics Trading Down 5.2%

RNAC stock opened at $8.55 on Tuesday. The firm has a 50-day moving average price of $7.24 and a 200-day moving average price of $8.15. Cartesian Therapeutics has a 12 month low of $5.98 and a 12 month high of $18.80. The stock has a market capitalization of $222.30 million, a P/E ratio of -1.67 and a beta of 0.42.

Cartesian Therapeutics (NASDAQ:RNAC) last announced its quarterly earnings results on Monday, March 9th. The company reported ($1.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.56). The company had revenue of $0.95 million for the quarter, compared to the consensus estimate of $0.10 million. As a group, equities analysts predict that Cartesian Therapeutics will post 4.56 EPS for the current fiscal year.

Insider Activity at Cartesian Therapeutics

In other news, CFO Blaine Davis sold 10,591 shares of Cartesian Therapeutics stock in a transaction that occurred on Tuesday, January 6th. The stock was sold at an average price of $6.82, for a total value of $72,230.62. Following the sale, the chief financial officer directly owned 121,220 shares in the company, valued at approximately $826,720.40. This trade represents a 8.03% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 60.30% of the company’s stock.

Institutional Trading of Cartesian Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the business. AlphaQuest LLC increased its stake in shares of Cartesian Therapeutics by 64.6% in the 3rd quarter. AlphaQuest LLC now owns 6,924 shares of the company’s stock worth $71,000 after acquiring an additional 2,717 shares in the last quarter. R Squared Ltd bought a new stake in Cartesian Therapeutics during the fourth quarter worth about $74,000. Wells Fargo & Company MN boosted its stake in Cartesian Therapeutics by 49.2% during the fourth quarter. Wells Fargo & Company MN now owns 11,762 shares of the company’s stock worth $85,000 after acquiring an additional 3,878 shares in the last quarter. Virtus Investment Advisers LLC grew its holdings in Cartesian Therapeutics by 12.5% in the second quarter. Virtus Investment Advisers LLC now owns 9,183 shares of the company’s stock worth $95,000 after purchasing an additional 1,023 shares during the period. Finally, Miller Financial Services LLC grew its holdings in Cartesian Therapeutics by 17.2% in the fourth quarter. Miller Financial Services LLC now owns 13,643 shares of the company’s stock worth $98,000 after purchasing an additional 2,000 shares during the period. 86.95% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Cartesian Therapeutics

Here are the key news stories impacting Cartesian Therapeutics this week:

• Positive Sentiment: Needham reaffirmed a “buy” and set a $42.00 price target (large upside vs. current levels), signaling strong analyst conviction that could support the stock over the medium term. Needham Rating
• Positive Sentiment: Cantor Fitzgerald upgraded RNAC from “neutral” to “overweight” and published a $16.00 target, adding nearer-term analyst buying pressure. Cantor Fitzgerald Upgrade
• Positive Sentiment: Wedbush reaffirmed an “outperform” rating with a $38.00 target — another bullish third-party signal that highlights sizable upside at several brokers. Wedbush Reaffirmation
• Neutral Sentiment: Short-interest reports for early March show 0 shares short (reports contain NaN/inconsistent values). This suggests no reported short pressure but the data appears unreliable/empty and shouldn’t be over-interpreted. Short Interest Report
• Negative Sentiment: Q4/Full‑Year 2025 results: RNAC missed consensus EPS materially (reported GAAP loss per share larger than expected) despite a revenue beat; the EPS miss is the most direct near‑term negative catalyst and likely explains part of the down pressure. Earnings & Business Update

Cartesian Therapeutics Company Profile

Cartesian Therapeutics, trading on NASDAQ under the symbol RNAC, is a clinical‐stage biotechnology company specializing in the development of messenger RNA (mRNA)-based therapeutics. The company leverages a proprietary RNA delivery platform to induce the production of therapeutic proteins within patients, aiming to address a range of diseases through in vivo expression of disease-modifying agents. Cartesian’s technology is designed to optimize mRNA stability, translation efficiency and targeted delivery, with potential applications spanning oncology, autoimmune disorders and rare genetic conditions.

At the core of Cartesian’s approach is a synthetic mRNA platform that incorporates proprietary lipid nanoparticle (LNP) formulations.